Proactive’s Post

High-Risk, High-Reward Alert: Greenwich LifeSciences, Inc. ($GLSI), a Healthcare sector company, saw insider trading by Patel Snehal, a Director, 10%+ Owner, CEO, and CFO, acquiring $65k worth of Common Stock. This indicates confidence in the company's future. Snehal's history includes a 178.88% mean ROI in 32 weeks from 35 past transactions, but there were also significant losses. At $8 per share, $GLSI is worth considering given Patel's mixed track record. Follow us for more insights! #Investing #GreenwichLifeSciences

Good article in The Times this morning highlighting my concerns that Exec Directors are being rewarded at the expense of shareholders. This is the wrong deal, wrong time at the wrong price. https://lnkd.in/e-jpFc8X

Zoetis recently published the 2023 Annual Report. Thanks to our talented colleagues around the world who helped deliver another year of strong growth and shareholder value. Dive deeper into the results with the full Annual Report here:  https://lnkd.in/eg4PDgRr #Investors #AnnualReport #AnimalHealth #FinancialResults

A Year from Now You May Wish You Had Started Today Unleashing the Potential of HSA Investing for a Secure Future! 💰💪🏼 Catalent Set to Bring Earnings Fireworks in September, with Triple-Digit Growth! 📊🚀 Summary: Mark your calendars for an exciting financial revelation! Catalent, a leading healthcare solutions provider, is poised to announce its Q4 earnings this September. Industry analysts are projecting a remarkable triple-digit growth on the bottom line, making it an investment opportunity not to be missed! 🔥💼 Investing in Your Health Savings Account (HSA) is More Important Than Ever! 💪🌟 With the rising importance of healthcare, it's crucial to optimize your financial decisions for the benefit of your family and overall wellness. HSA accounts provide an exceptional opportunity to grow your investments while safeguarding your future healthcare needs. Don't let FOMO (Fear of Missing Out) hold you back - take action today, and empower yourself financially! 💯😊 Hashtags: #hsa #investing #healthcare #health #family #wellness Emojis: 💰💪🏼📊🚀💼💯😊

It is common for private limited companies that are incorporated in England and Wales to have a sole director who is also the sole shareholder of the company. Therefore, problems arise if no provisions are in place should the director and shareholder die whilst in these roles. In our latest Kitson Boyce Insight, Corri Pedrick, Partner and Head of our Corporate team discusses what happens next in these circumstances. Read article here: https://lnkd.in/eSnWYPdT. #corporatelaw #kbinsight #kitsonboycellp

A year from now you may wish you had started today Investing in Bristol-Myers Squibb: Seizing the Opportunity to Grow Your HSA Account 💰💪 Don't Miss Out on Potential Gains! Act Now to Boost Your #HSA #Investing 💰💪 Bristol-Myers Squibb, a renowned healthcare company, is set to announce its second-quarter results this month. Analysts anticipate a slight decline in the company's bottom-line figure. However, as a seasoned investment advisor, I urge you not to let fear of missing out hinder your potential for growth. 📈 Why Bristol-Myers Squibb? Bristol-Myers Squibb is a leading player in the healthcare industry, delivering innovative solutions that impact millions of lives. With a solid track record and a commitment to excellence, the company presents a promising opportunity for HSA investors seeking long-term growth. ⚡️ The Power of Investing Investing in the healthcare sector through your HSA account allows you to align your financial goals with your commitment to personal well-being and family health. By putting your money to work in this sector, you can contribute to advancements in medical research, drug development, and improved healthcare access. 🔒 Overcoming the Fear of Missing Out Don't let hesitation hold you back from seizing this opportunity to optimize your HSA investments. Start today and position yourself for potential gains in the future. Take action and invest in Bristol-Myers Squibb to diversify your portfolio and benefit from the growing healthcare market. 🚀 Maximizing Your HSA Potential Investing wisely in healthcare not only contributes to your financial growth but also helps secure your family's well-being. By leveraging your HSA account, you can enjoy tax advantages while simultaneously supporting the advancement of medical breakthroughs and the improvement of global healthcare. 💼 Unlock the Potential of Your HSA Account Take charge of your financial future and leverage the power of HSA investing with Bristol-Myers Squibb. Act now to capitalize on this opportunity and enjoy the benefits of long-term growth, financial stability, and a positive impact on the world. #HSA #Investing #Healthcare #Health #Family #Wellness 📈💪🏥🌱💰

Bristol-Myers Squibb Stock: Overcoming Market Challenges and Embracing Opportunities 📈💡 Invest in HSA, Multiply Your Health! Summary: Bristol-Myers Squibb (BMY) stock has faced its fair share of challenges this year, leading to underperformance compared to the broader market. Despite this setback, the potential for growth in the healthcare sector remains promising. As investment advisors with a passion for leveraging HSA accounts, we believe it is crucial to look beyond short-term fluctuations and focus on long-term opportunities. Wall Street's Worries: Critics have voiced concerns regarding the stock's prospects, raising questions about Bristol-Myers Squibb's ability to regain momentum. These apprehensions, combined with uncertain economic conditions, have added to investor caution. Nonetheless, the healthcare industry presents an incredible opportunity for HSA investors seeking reliable growth. Unleashing Potential: Bristol-Myers Squibb's expertise in pharmaceuticals positions them uniquely to capitalize on the growing demand for innovative healthcare solutions. Furthermore, their robust pipeline of potential breakthrough drugs showcases the company's commitment to research and development. By aligning your HSA investments with reputable healthcare companies like Bristol-Myers Squibb, you can leverage the potential for both financial and personal growth. Act Now! 💪🚀 Don't let fear hold you back from seizing potential gains and making a positive impact on your health, family, and wellness. Invest in HSA accounts today and tap into the future of healthcare. Stay ahead of the curve and explore the endless possibilities within the healthcare industry. #HSA #investing #healthcare #health #family #wellness 📊💰💪

The 12/19 Healthcare Labyrinth Newsfeed is live! Click below to read! Some of today's topics: -- Antitrust guidelines finalized -- DOJ opposes Humana RADV suit -- DOJ Fights IRA Medicare drug pricing suit -- Will there be biosimilar uptake? -- Findings on the underinsured #healthcare #healthinsurance #healthcarereform #healthcarelabyrinth

Since being charged by US federal prosecutors in July, Joe Lewis, the British billionaire behind one of the world’s biggest investing fortunes, has repeatedly traded shares of Mirati Therapeutics Inc., Australian Agricultural Co. and Tango Therapeutics Inc., according to data compiled by Bloomberg from regulatory filings. His stakes in those companies — three of the five behind the indictment’s claims — total about $540 million. The recent trades give an insight into Lewis’s business activities since he was arrested after voluntarily surrendering in New York, making him the highest-profile investor swept up in a recent insider-trading crackdown by federal prosecutors. Ben Stupples - Bloomberg - Yahoo Finance - Mirati Therapeutics - Australian Agricultural Company (AACo) - Tango Therapeutics #insidertrading #financialcrime #wallstreet #globalmarkets #pharmaceuticalindustry

#PattersonCompanies revised its fiscal 2024 earnings guidance lower after facing softer market demand, sending shares tumbling on Wednesday. The company now expects its adjusted earnings per share (EPS) projection to be in the range of $2.35 to $2.45, compared to the previous guidance of $2.45 to $2.55. Despite the disappointing forecast, Patterson revealed a 1.6% year-over-year increase in consolidated net sales, totaling $1.65 billion, which just missed Zacks Consensus Estimates. Despite the sales growth, Patterson Companies witnessed a decline in net income attributable to the company, recording $40 million, or $0.42 per diluted share, down from $54.1 million, or $0.55 per diluted share, in the second quarter of fiscal 2023. Adjusted net income, excluding deal amortization, stood at $47.3 million, or $0.50 per diluted share, in contrast to $61.2 million, or $0.63 per diluted share, in the previous year. More at #Proactive #ProactiveInvestors http://ow.ly/Yu3Y1054bjg